EKC Q1 FY26 Revenue Jumps 12.9% to ₹386.9 Cr, PAT Up 84.9%; Capacity Expansion Progresses
The announcement details robust financial results for Q1 FY26, including substantial increases in revenue and profit. Crucially, it outlines ongoing large-scale capacity expansions in India and Egypt, which are expected to significantly boost future supply capabilities and revenue from FY27. Furthermore, the company's strategic focus on emerging sectors like compressed biogas, semiconductors, and green hydrogen indicates a clear path for sustained growth and market leadership.
The company reported strong year-on-year growth in consolidated revenue (12.9%), EBITDA (47.8%), and PAT (84.9%). Indian and US operations showed robust performance, and significant capacity expansions are on track, signaling future growth. The management expressed a positive outlook for the year.
* For the quarter ended June 30, 2025 (Q1 FY26): * Consolidated revenue grew by 12.9% year-on-year (YoY) to ₹386.9 crore. * Consolidated EBITDA increased by 47.8% YoY to ₹61.3 crore, with a margin of 15.8%. * Consolidated Profit After Tax (PAT) surged by 84.9% YoY to ₹51.6 crore. This includes an exceptional gain of ₹12.6 crore from an Employee Retention Credit (ERC) received by its US subsidiary. * Indian operations reported a 20.9% YoY revenue increase to ₹237 crore and PAT up 122.8% YoY to ₹26.1 crore, with margins improving to 17.2% from 9.4% in Q1 FY25. * The US business saw revenues rise 21% YoY to ₹109 crore and EBIT grow 83% YoY to ₹27 crore, holding an order book of USD 70 million. * New facilities in Mundra, India, and Egypt are progressing as planned and are expected to commence production during the current fiscal year (FY26), with significant impact from FY27. * The Egypt facility (120,000 units capacity, ₹120 crore CAPEX) anticipates trial production in October-November 2025. * The Mundra facility (200,000 units capacity, ₹125 crore CAPEX) is set for commercial production by the end of FY26. * The company is actively exploring new opportunities in compressed biogas, semiconductors, and green hydrogen segments. * Management anticipates 10-15% growth and sustainable margins of 13-14% for the Indian business in FY26, and expects the US market to perform exceptionally well. * Consolidated gross debt is ₹140 crore, with net debt close to zero, as CAPEX is funded through internal accruals and borrowings, aiming to maintain a net debt-free position. * Mr. Puneet Khurana, Managing Director, stated that FY26 has begun on a strong note and the company is well-positioned for the next phase of growth. Mr. Sanjiv Kapur, CFO, expressed confidence in resolving a contingent GST liability of ₹352 crore.
What to do with a filing like this
Everest Kanto Cylinder Limited filed this with the NSE as a statutory disclosure, categorised under results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Everest Kanto Cylinder Limited. Read the original for the full detail.